Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Not Applicable

• Conditions: Inoperable advanced/recurrence Gastric Cancer or Esophageal Cancer or Colorectal Cancer

• Registration Number: JPRN-UMIN000013782
• Lead Sponsor: Osaka Medical College Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-22
• Study Completion: 2018-07-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patient who is taking Pimozide. (2) Patient who has severe liver failure or renal failure. (3) Patient who had been treated with one moderate risk emetogenic antitumour drug according to the 2014 National Comprehensive Cancer Network Clinical Practice Guidelines. (4) Patient who has vomited or provoked nausea in the 24 hours prior to start of chemotherapy. (5) Patient who is considered inappropriate as a target patient by a physician-in-charge.

Study & Design

• Study Type: Interventional
• Study Design: Not specified